Together with our partners, Ably is developing technologies that efficiently integrate patient treatment, practical nursing and medical research. At the core of our collaborative work, is the redesigned hospital bed for the 21st century. The bed is dynamic and intelligent, addressing key issues in global healthcare today.
AOT's CARLO-system (Cold Ablation Robot-Guided Laser Osteotome) works more precisely than a human being ever could. For that reason, it opens up the door to more gentle treatment possibilities, keeping bone tissue vital and intact at the site of the laser incision. The CARLO-system enables the direct collaboration of man and machine by means of a small, lightweight, and custom-designed tactile robotic arm, as well as navigation and control software and its corresponding hardware. All of these elements are combined in an ergonomic system, which fits easily into the operating room and allows the surgeon full control over this universal osteotomy device at any time. CARLO is thus the world's first medical, tactile robot that can cut bone without contact and with cold laser technology. The device allows the surgeon to perform bone operations with unprecedented precision, and in freely-defined, curved and functional sectional configurations, which are not achievable with conventional instruments.
BAYOOMED is the medical software division of BAYOONET Inc. Here we combine medical professional know-how with our software development expertise. We serve more than 800 clients from the pharmaceutical and medical technology sector, and we specialize in the development of medical (standalone) software and medical apps (iOS, Android, Windows 8).
Boston Neurosciences (BNS) is a clinical-stage, venture-backed company headquartered in Boston with ISO 13485-certified operations in Lithuania, focused on the development of a non-invasive intracranial pressure monitoring platform for the diagnosis of altered intracranial pressure dynamics for neurological and ophthalmological applications. Its first product is a self-calibrating instrument that uses image-guided transcranial Doppler ultrasound technology to measure intracranial pressure.
The underlying technology was developed at the Kaunas University of Technology. The Company was founded in 2013.
BrainsWay is dedicated to developing and providing advanced solutions for brain disorders. The company was established in 2003, and became a public company traded on the Tel-Aviv Stock Exchange in January 2007. BrainsWay’s flagship technology, which is based on Deep Transcranial Magnetic Stimulation (TMS), launches a new era in brain disorder treatment.
BrainsWay’s treatment is based on patents filed by the U.S. National Institutes of Health (NIH), and by the company. The company holds an exclusive license from the NIH for the patent and for its unique technology.
BrainsWay’s treatment is FDA-cleared for treating depressive episodes in adult patients suffering from Major Depressive Disorder, who failed to achieve satisfactory improvement from previous anti-depressant medication treatment in the current episode (FDA 510(k) No. K122288).
BrainsWay runs clinical research programs with leading scientists worldwide, collaborating with prominent institutions and researchers in clinical trials covering various neuropsychiatric and neuroscience applications.
The company’s technology has already helped thousands of people worldwide in both private clinics and clinical studies. It has also been enthusiastically embraced by leading research institutions worldwide, with over 60 clinical trials held around the globe.
Medyria is a Swiss medtech startup that engineers technologies for endovascular catheter navigation and sensing.
In 2013, Dr. Mauro Sette came with the idea of incubating a project on the tracking of catheters. In 2014, Medyria AG was effectively incorporated and funded. Three years later, in 2017, Medyria AG has successfully developed an innovative and proprietary blood flow velocity measuring catheter.
The TrackCath System is designed to support cannulation during Endovascular Aneurysm Repair procedures.
Medyria AG is located in Technopark, Winterthur, Switzerland.
Our goal is to develop devices that enable safer and more effective endovascular procedures.
One must remember the notion that restoring some vision to those who have lost their sight is possible, has long been thought to be fanciful. However, we are in the Age of Neural Prostheses, Bioelectronics, and BMI. At frontier of neuroscience, interfacing the worlds of eye and the brain – “from Photons to Neurons”. Such is the breadth and depth of knowledge needed to build a world of bionic vision for those with vision loss. This is the mission of Pixium Vision.
Two novel life changing Bionic Vision Systems developed, with active implantable prostheses, that are intended to compensate for vision loss and blindness from retinal degeneration, like Dry Age-Related Macular Degeneration (AMD) and Retinitis Pigmentosa (RP), enabling to regain partial central visual perception and lead more independent lives.
Advances in neuro-ophthalmology, innovative state of the art biomedical / bioelectronic technologies, smart bio-inspired bio-mimetic algorithms and AI, and miniaturization of micro/nano-electronics, enable minimal invasive retinal surgery, and develop systems that could provide blind people with a form of prosthetic bionic vision.
• PRIMA (Subretinal) a miniaturized wireless photovoltaic implant platform initially for Dry-AMD. The company is conducting first-in-human feasibility trials in Europe and the US. • IRIS®II (Epiretinal) its first System for RP, equipped with a bio-inspired camera, an implant with 150 electrodes, designed to be explantable.
Formed in Dec 2011, a bioelectronics technology company specialized in neuromodulation to restore a form of prosthetic vision to compensate for blindness. Listed on Euronext Paris stock exchange in June 2014. Collaborates with a global ecosystem of scientific and clinical partners spanning the prestigious Vision research institutions including: Institut de la Vision Paris, Stanford University California, Moorfields Eye Hospital London, and Institute of Ocular Microsurgery (IMO) Barcelona.
The microbiome is the ecosystem of micro-organisms that live in and around us, mostly in our gut. It plays a major role in human health, and when out of balance causes diseases such as chronic digestive disorders, diabetes, obesity, allergies, auto-immune diseases and much else.
We have a genotype and a phenotype. What everyone also has is a "microtype:" The composition of the microbiome. It affects the response to treatments as well as our food and lifestyle.
REM Analytics provides a novel method to profile the microtype in people. For companies producing probiotics, prebiotics, functional foods or other microbiome affecting products, we provide the evidence needed to demonstrate the efficacy of your products.
We have the unique capability to measure the colonization of specific probiotic strain in the microbiome of people. Also, we can measure the effect of these strains on the microtype at large, as well as differences induced by changes in food and lifestyle. Accurate profiling of the microtype has the potential to identify sub-populations that are more likely to be treated by a probiotic.
In the long run, our objecitve is to allow the development of Evidence-based, personalised microbiome based treatments.
Resistell proposes an alternative to culture based antibiogram, the current gold standard in antibiotic susceptibility testing. Our offering is a diagnostic device. The rapid AST method is based on the detection of movement caused by living bacterial cells. Because the test is growth independent rapid AST, we reduce the time taken to get a result from days to minutes. Resistell provides information on which antibiotic should be used to treat the patient, and the concentration at which it should be administered.